Selective estrogen receptor-β agonists repress transcription of proinflammatory genes

Journal of Immunology

Volumn 180, Issue 1, 2008, Pages 630-636

  Cvoro, Aleksandra ^a   Tatomer, Deirdre ^a   Tee, Meng Kian ^a   Zogovic, Tatjana ^a   Harris, Heather A ^b   Leitman, Dale C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HORMONE RECEPTOR STIMULATING AGENT; INTERLEUKIN 6; NUCLEAR RECEPTOR COACTIVATOR 2; PRINABEREL; TUMOR NECROSIS FACTOR ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT; OXAZOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; DNA MICROARRAY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; INFLAMMATION; MONONUCLEAR CELL; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; CYTOKINES; DOWN-REGULATION; ESTROGEN RECEPTOR BETA; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXAZOLES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40449107415     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Vural, P., C. Akgul, and M. Canbaz. 2006. Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol. Res. 54: 298-302.
2. Pfeilschifter, J., R. Koditz, M. Pfohl, and H. Schatz. 2002. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 23: 90-119.
3. Romas, E., and T. J. Martin. 1997. Cytokines in the pathogenesis of osteoporosis. Osteoporos. Int. 7: S47-53.
4. Pacifici, R. 1996. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 11: 1043-1051.
5. Cacquevel, M., N. Lebeurrier, S. Cheenne, and D. Vivien. 2004. Cytokines in neuroinflammation and Alzheimer's disease. Curr. Drug Targets 5: 529-534.
6. Ferrari, R. 1999. The role of TNF in cardiovascular disease. Pharmacol. Res. 40: 97-105.
7. Yasui, T., M. Maegawa, J. Tomita, Y. Miyatani, M. Yamada, H. Uemura, T. Matsuzaki, A. Kuwahara, M. Kamada, N. Tsuchiya, et al. 2007. Changes in serum cytokine concentrations during the menopausal transition. Maturitas 56: 396-403.
8. Hu, F. B., and F. Grodstein. 2002. Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence. Am. J. Cardiol. 90: 26F-29F.
9. van Duijn, C. M. 1999. Hormone replacement therapy and Alzheimer's disease. Maturitas 31: 201-205.
10. Johnson, S. R. 1998. Menopause and hormone replacement therapy. Med. Clin. North Am. 82: 297-320.
11. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288: 321-333.
12. Rossouw, J. E., R. L. Prentice, J. E. Manson, L. Wu, D. Barad, V. M. Barnabei, M. Ko, A. Z. LaCroix, K. L. Margolis, and M. L. Stefanick. 2007. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J. Am. Med. Assoc. 297: 1465-1477.
13. Weitzmann, M. N., and R. Pacifici. 2006. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 116: 1186-1194.
14. Ralston, S. H., R. G. Russell, and M. Gowen. 1990. Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J. Bone Miner. Res. 5: 983-988.
15. Dahlman-Wright, K., V. Cavailles, S. A. Fuqua, V. C. Jordan, J. A. Katzenellenbogen, K. S. Korach, A. Maggi, M. Muramatsu, M. G. Parker, and J. A. Gustafsson. 2006. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev. 58: 773-781.
16. Koehler, K. F., L. A. Helguero, L. A. Haldosen, M. Warner, and J. A. Gustafsson. 2005. Reflections on the discovery and significance of estrogen receptor β. Endocr. Rev. 26: 465-478.
17. Ray, P., S. K. Ghosh, D. H. Zhang, and A. Ray. 1997. Repression of interleukin-6 gene expression by 17β-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-κB by the estrogen receptor. FEBS Lett. 409: 79-85.
18. Stein, B., and M. X. Yang. 1995. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ. Mol. Cell. Biol. 15: 4971-4979.
19. Cvoro, A., C. Tzagarakis-Foster, D. Tatomer, S. Paruthiyil, M. S. Fox, and D. C. Leitman. 2006. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol. Cell 21: 555-564.
20. Chadwick, C. C., S. Chippari, E. Matelan, L. Borges-Marcucci, A. M. Eckert, J. C. Keith, Jr., L. M. Albert, Y. Leathurby, H. A. Harris, R. A. Bhat, et al. 2005. Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity. Proc. Natl. Acad. Sci. USA 102: 2543-2548.
21. Hewitt, S. C., J. C. Harrell, and K. S. Korach. 2005. Lessons in estrogen biology from knockout and transgenic animals. Annu. Rev. Physiol. 67: 285-308.
22. 2 cell cycle arrest. Cancer Res. 64: 423-428.
23. Strom, A., J. Hartman, J. S. Foster, S. Kietz, J. Wimalasena, and J. A. Gustafsson. 2004. Estrogen receptor β inhibits 17β-estradiol- stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. USA 101: 1566-1571.
24. Lazennec, G., D. Bresson, A. Lucas, C. Chauveau, and F. Vignon. 2001. ERβ inhibits proliferation and invasion of breast cancer cells. Endocrinology 142: 4120-4130.
25. An, J., R. C. Ribeiro, P. Webb, J. A. Gustafsson, P. J. Kushner, J. D. Baxter, and D. C. Leitman. 1999. Estradiol repression of tumor necrosis factor-α transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc. Natl. Acad. Sci. USA 96: 15161-15166.
26. Manas, E. S., R. J. Unwalla, Z. B. Xu, M. S. Malamas, C. P. Miller, H. A. Harris, C. Hsiao, T. Akopian, W. T. Hum, K. Malakian, et al. 2004. Structure-based design of estrogen receptor-β selective ligands. J. Am. Chem. Soc. 126: 15106-15119.
27. Harris, H. A., L. M. Albert, Y. Leathurby, M. S. Malamas, R. E. Mewshaw, C. P. Miller, Y. P. Kharode, J. Marzolf, B. S. Komm, R. C. Winneker, et al. 2003. Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 144: 4241-4249.
28. Ulziibat, S., K. Ejima, Y. Shibata, Y. Hishikawa, M. Kitajima, A. Fujishita, T. Ishimaru, and T. Koji. 2006. Identification of estrogen receptor β-positive intraepithelial lymphocytes and their possible roles in normal and tubal pregnancy oviducts. Hum. Reprod. 21: 2281-2289.
29. Harris, H. A., K. L. Bruner-Tran, X. Zhang, K. G. Osteen, and C. Richard Lyttle. 2005. A selective estrogen receptor-β agonist causes lesion regression in an experimentally induced model of endometriosis. Hum. Reprod. 20: 936-941.
30. Harris, H. A. 2007. Estrogen receptor-β: recent lessons from in vivo studies. Mol. Endocrinol. 21: 1-13.
31. Crabtree, J. S., X. Zhang, B. J. Peano, Z. Zhang, R. C. Winneker, and H. A. Harris. 2006. Development of a mouse model of mammary gland versus uterus tissue selectivity using estrogen- and progesterone-regulated gene markers. J. Steroid Biochem. Mol. Biol. 101: 11-21.
32. Cristofaro, P. A., S. M. Opal, J. E. Palardy, N. A. Parejo, J. Jhung, J. C. Keith, Jr., and H. A. Harris. 2006. WAY-202196, a selective estrogen receptor-β agonist, protects against death in experimental septic shock. Crit. Care Med. 34: 2188-2193.
33. Follettie, M. T., M. Pinard, J. C. Keith, Jr., L. Wang, D. Chelsky, C. Hayward, P. Kearney, P. Thibault, E. Paramithiotis, A. J. Dorner, and H. A. Harris. 2006. Organ messenger ribonucleic acid and plasma proteome changes in the adjuvant-induced arthritis model: responses to disease induction and therapy with the estrogen receptor-β selective agonist ERB-041. Endocrinology 147: 714-723.
34. Mewshaw, R. E., R. J. Edsall, Jr., C. Yang, E. S. Manas, Z. B. Xu, R. A. Henderson, J. C. Keith, Jr., and H. A. Harris. 2005. ERβ ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERβ selectivity. J. Med. Chem. 48: 3953-3979.
35. Malamas, M. S., E. S. Manas, R. E. McDevitt, I. Gunawan, Z. B. Xu, M. D. Collini, C. P. Miller, T. Dinh, R. A. Henderson, J. C. Keith, Jr., and H. A. Harris. 2004. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands. J. Med. Chem. 47: 5021-5040.
36. Stauffer, S. R., C. J. Coletta, R. Tedesco, G. Nishiguchi, K. Carlson, J. Sun, B. S. Katzenellenbogen, and J. A. Katzenellenbogen. 2000. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-α-selective agonists. J. Med. Chem. 43: 4934-4947.
37. Tzagarakis-Foster, C., R. Geleziunas, A. Lomri, J. An, and D. C. Leitman. 2002. Estradiol represses human T-cell leukemia virus type 1 Tax activation of tumor necrosis factor-α gene transcription. J. Biol. Chem. 277: 44772-44777.
38. Kian Tee, M., I. Rogatsky, C. Tzagarakis-Foster, A. Cvoro, J. An, R. J. Christy, K. R. Yamamoto, and D. C. Leitman. 2004. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol. Biol. Cell 15: 1262-1272.
39. Burakov, D., L. A. Crofts, C. P. Chang, and L. P. Freedman. 2002. Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor. J. Biol. Chem. 277: 14359-14362.
40. Choi, I., L. J. Gudas, and B. S. Katzenellenbogen. 2000. Regulation of keratin 19 gene expression by estrogen in human breast cancer cells and identification of the estrogen responsive gene region. Mol. Cell. Endocrinol. 164: 225-237.
41. Chakrabarti, S. K., J. C. James, and R. G. Mirmira. 2002. Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1: importance of chromatin structure in directing promoter binding. J. Biol. Chem. 277: 13286-13293.
42. Stygar, D., B. Masironi, H. Eriksson, and L. Sahlin. 2007. Studies on estrogen receptor (ER) α and β responses on gene regulation in peripheral blood leukocytes in vivo using selective ER agonists. J. Endocrinol. 194: 101-119.
43. Stygar, D., P. Westlund, H. Eriksson, and L. Sahlin. 2006. Identification of wild type and variants of oestrogen receptors in polymorphonuclear and mononuclear leucocytes. Clin. Endocrinol. 64: 74-81.
44. Volpato, S., J. M. Guralnik, L. Ferrucci, J. Balfour, P. Chaves, L. P. Fried, and T. B. Harris. 2001. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation 103: 947-953.
45. Boekholdt, S. M., R. J. Peters, C. E. Hack, N. E. Day, R. Luben, S. A. Bingham, N. J. Wareham, P. H. Reitsma, and K. T. Khaw. 2004. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler. Thromb. Vasc. Biol. 24: 1503-1508.
46. Hall, J. M., and D. P. McDonnell. 1999. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140: 5566-5578.
47. McInnes, I. B., and F. Y. Liew. 2005. Cytokine networks-towards new therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1: 31-39.
48. Wu, M. Y., and H. N. Ho. 2003. The role of cytokines in endometriosis. Am. J. Reprod. Immunol. 49: 285-296.
49. Vegeto, E., S. Belcredito, S. Etteri, S. Ghisletti, A. Brusadelli, C. Meda, A. Krust, S. Dupont, P. Ciana, P. Chambon, and A. Maggi. 2003. Estrogen receptor-α mediates the brain antiinflammatory activity of estradiol. Proc. Natl. Acad. Sci. USA 100: 9614-9619.
50. Stork, S., Y. T. van der Schouw, D. E. Grobbee, and M. L. Bots. 2004. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol. Metab. 15: 66-72.
51. Couse, J. F., J. Lindzey, K. Grandien, J. A. Gustafsson, and K. S. Korach. 1997. Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse. Endocrinology 138: 4613-4621.
52. Kuiper, G. G., B. Carlsson, K. Grandien, E. Enmark, J. Haggblad, S. Nilsson, and J. A. Gustafsson. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138: 863-870.
53. Xing, D., W. Feng, A. P. Miller, N. M. Weathington, Y. F. Chen, L. Novak, J. E. Blalock, and S. Oparil. 2007. Estrogen modulates TNF-α-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-β activation. Am. J. Physiol. 292: H2607-H2612.
54. Karas, R. H., J. B. Hodgin, M. Kwoun, J. H. Krege, M. Aronovitz, W. Mackey, J. A. Gustafsson, K. S. Korach, O. Smithies, and M. E. Mendelsohn. 1999. Estrogen inhibits the vascular injury response in estrogen receptor β-deficient female mice. Proc. Natl. Acad. Sci. USA 96: 15133-15136.
55. Phiel, K. L., R. A. Henderson, S. J. Adelman, and M. M. Elloso. 2005. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol. Lett. 97: 107-113.
56. Cvoro, A., S. Paruthiyil, J. O. Jones, C. Tzagarakis-Foster, N. J. Clegg, D. Tatomer, R. T. Medina, M. Tagliaferri, F. Schaufele, T. S. Scanlan, et al. 2007. Selective activation of estrogen receptor-β transcriptional pathways by an herbal extract. Endocrinology 148: 538-547.